Damaged Protein Identified As Early Diagnostic Biomarker For Alzheimer's Disease In Health Adults
February 25, 2010
Adapted from the New York University School of Medicine
Researchers at New York University (NYU) School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer’s disease, may be an early diagnostic biomarker for Alzheimer’s disease in healthy adults.
The study, published this month online by <i>Neurobiology of Aging</i>, shows that high levels of P-tau231 predict future memory decline and loss of brain gray matter in the medial temporal lobe—a key memory center. Prior studies found the medial temporal lobe to be the most vulnerable brain region in the early stages of Alzheimer’s disease, accumulating damaged tau proteins in the form of neurofibrillary tangles. Tangles are one of the signature indicators of Alzheimer’s disease, in addition to beta amyloid plaques.
“Our research results show for the first time that elevated levels of P-tau 231 in normal individuals can predict memory decline and accompanying brain atrophy,” said lead author Lidia Glodzik M.D., Ph.D., assistant research professor, Department of Psychiatry at the Center for Brain Health and Center of Excellence on Brain Aging at NYU School of Medicine. “Our findings suggest that P-tau231 has the potential to be an important diagnostic tool in the pre-symptomatic stages of Alzheimer’s disease.”
“Indentifying people at risk for Alzheimer’s disease is the necessary first step in developing preventive therapies,” said co-author Mony de Leon, Ed.D., professor, Department of Psychiatry, and director of the Center for Brain Health at the Center of Excellence on Brain Aging at NYU School of Medicine and research scientist at the Nathan S. Kline Institute for Psychiatric Research. “This study shows that Alzheimer’s disease pathology may be recognized in the normal stages of cognition. This observation may be of value in future studies investigating mechanisms that cause or accelerate dementia.”
On behalf of its donors, Alzheimer's Disease Research (ADR), program of the American Health Assistance Foundation (AHAF), is very proud to have previously funded Dr. Mony de Leon concerning a project exploring the pre-clinical diagnosis of Alzheimer’s disease.
View all news updates for Alzheimer's disease
Disclaimer: The information provided in this section is a public service of the American Health Assistance Foundation, and should not in any way substitute for the advice of a qualified healthcare professional and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. The American Health Assistance Foundation does not endorse any medical product or therapy.
Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.
